This page shows the latest tucatinib news and features for those working in and with pharma, biotech and healthcare.
The MHRA has cleared Tukysa (tucatinib) as an add-on therapy to Roche’s anti-HER2 antibody Herceptin (trastuzumb) plus Xeloda (capecitabine) for adults patients with HER2-positive locally-advanced or
In a separate agreement, Seattle Genetics has granted Merck an exclusive license to commercialise Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, in Asia, the Middle East, Latin America and other
Seattle is seeking approval for tucatinib in combination with Roche’s anti-HER2 antibody (trastuzumab) plus Xeloda (capecitabine). ... If Seattle does gain approval for tucatinib, it will go on to compete with rival HER2 inhibitor Enhertu, marketed by
In the meantime, further HER2 competition could be coming from Seattle Genetics’ oral drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus
Also on the horizon is Seattle Genetics’ oral HER2 drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus Roche’s chemotherapy Xeloda (capecitabine) ... HER2CLIMB-02 will compare tucatinib to placebo in
Also looking to encroach on the HER2 market is Seattle Genetics, with its orally-active HER2 inhibitor tucatinib.
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Undeterred Seattle Genetics went on to buy Cascadian Therapeutics at the very end of January for
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...